Which is better, ustekinumab or secukinumab?

Ustekinumab and secukinumab are two different biologics used to treat autoimmune diseases, specifically psoriasis and psoriatic arthritis. The two drugs have some similarities, but also some differences. Results from a clinical study show that secukinumab is superior to ustekinumab at clearing the skin and improving health-related quality of life in patients with moderate to severe psoriasis and has a comparable safety profile for 16 weeks.

Ustekinumab is a monoclonal antibody against interleukin-12 and -23 (IL-12/23). It reduces the inflammatory response by inhibiting the action of these cytokines, thereby alleviating the condition. Secukinumab is a monoclonal antibody against interleukin-17A (IL-17A). It reduces the inflammatory response by inhibiting the effects of IL-17A, thereby improving symptoms of autoimmune diseases. Both ustekinumab and secukinumab have shown good clinical efficacy and may respond differently in different patients. Which drug is more suitable for a patient needs to be decided based on the specific situation and the doctor's advice.

The generic drug Ustekinumab has been launched in China and is included in the medical insurance, and is only reimbursed for patients who meet the indications. The price of the 130mg/26ml intravenous injection preparation may be more than 5,000 yuan per box, and the price of the 90mg: 1.0ml*1 subcutaneous injection preparation may be more than 8,000 yuan per box. The price of the 130mg/26ml intravenous injection preparation of Ustekinumab sold overseas may be more than 2,000 US dollars per box, and the price of 45mg: 0.5ml*1 subcutaneous injection preparation per box may be more than 10,000 US dollars. There are currently no generic versions of ustekinumab produced in other overseas countries.